Kiniksa Pharmaceuticals International logo

Kiniksa Pharmaceuticals International

KNSA | NASDAQ
Chart Builder DCF Calculator
$78.56
+$0.43 (+0.55%)
Sep 22, 2026, 1:41 PM ET · Market open
Fiscal Quarter
Period Ending
Q2 2026
Jun 29, 2026
Q1 2026
Mar 30, 2026
Q4 2025
Dec 30, 2025
Q3 2025
Sep 29, 2025
Q2 2025
Jun 29, 2025
Q1 2025
Mar 30, 2025
Q4 2024
Dec 30, 2024
Q3 2024
Sep 29, 2024
Q2 2024
Jun 29, 2024
Q1 2024
Mar 30, 2024
Q4 2023
Dec 30, 2023
Q3 2023
Sep 29, 2023
Q2 2023
Jun 29, 2023
Q1 2023
Mar 30, 2023
Q4 2022
Dec 30, 2022
Q3 2022
Sep 29, 2022
Q2 2022
Jun 29, 2022
Q1 2022
Mar 30, 2022
Q4 2021
Dec 30, 2021
Q3 2021
Sep 29, 2021
Q2 2021
Jun 29, 2021
Q1 2021
Mar 30, 2021
Revenue
243.6M 214.27M 202.13M 180.86M 156.8M 137.79M 122.54M 112.21M 108.63M 79.86M 83.4M 67.05M 71.47M 48.35M 61.88M 99.14M 26.97M 32.19M 18.75M 12.1M 7.7M n/a
Cost of Revenue
23.57M 96.37M 91.1M 83.59M 71.02M 61.66M 66.17M 49.42M 42.46M 31.54M 26.76M 27.4M 22.75M 16.45M 14.23M 12.51M 9.8M 13.57M 3.87M 3.84M 3.48M 883K
Gross Profit
220.03M 117.89M 111.03M 97.26M 85.76M 76.13M 56.36M 62.8M 66.18M 48.32M 56.64M 39.65M 48.73M 31.89M 47.65M 86.63M 17.18M 18.62M 14.88M 8.25M 4.22M -883K
Operating Income
27.19M 29.27M 19.77M 24.02M 20.16M 13.27M -19.3M -9.66M -117K -16.54M 81K -10.93M -3.15M -11.2M 6.05M 46.41M -19.37M -23.32M -36.13M -30.67M -40.56M -49.28M
Interest Income
3.95M 3.41M 2.72M 3.14M 2.72M 2.29M 2.32M 2.46M 2.42M n/a 2.37M 2.43M 1.92M 3.66M 794K 322K 103K 34K 77K 5K 6K 9K
Pretax Income
31.15M 32.68M 23.27M 27.16M 22.88M 15.57M -16.98M -7.2M 2.3M -14.28M 2.45M -8.5M -1.24M -9.36M 6.84M 46.74M -19.27M -23.29M -36.05M -30.66M -40.55M -49.27M
Net Income
25.43M 22.59M 14.2M 18.44M 17.83M 8.54M -8.89M -12.69M -3.91M -17.7M 25.24M -13.86M 14.97M -12.27M 4.46M 224.09M -19.98M -25.21M -36.33M -30.54M -41.56M -49.48M
Selling & General & Admin
63.87M 61.15M 56.78M 49.1M 46.86M 43.53M 40.54M 46.4M 42.4M 38.68M 36.74M 33.76M 28.41M 28.2M 27.22M 23.91M 23.1M 21.48M 22.74M 20.06M 21.25M 20.01M
Research & Development
40.9M 27.48M 34.64M 24.14M 18.75M 19.33M 35.13M 26.06M 23.9M 26.18M 19.82M 16.81M 23.48M 14.88M 14.39M 16.31M 13.45M 20.46M 27.43M 18.86M 23.53M 28.39M
Other Expenses
88.07M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 835K n/a n/a n/a
Operating Expenses
192.83M 88.63M 91.26M 73.24M 65.62M 62.86M 75.66M 72.46M 66.29M 64.86M 56.56M 50.58M 51.88M 43.09M 41.61M 40.21M 36.54M 41.94M 51.01M 38.92M 44.78M 48.4M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 1.83M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
216.41M 185M 182.36M 156.83M 136.64M 124.51M 141.84M 121.87M 108.75M 96.4M 83.31M 77.97M 74.63M 59.54M 55.84M 52.72M 46.34M 55.51M 54.88M 42.76M 48.26M 49.28M
Income Tax Expense
5.71M 10.09M 9.07M 8.72M 5.05M 7.03M -8.09M 5.49M 6.21M 3.43M -22.79M 5.36M -16.21M 2.91M 2.38M -177.36M 716K 1.93M 279K -118K 1.01M 210K
Shares Outstanding (Basic)
77.58M 76.52M 74.2M 73.61M 73.44M 72.65M 72.32M 71.73M 71M 70.63M 70.37M 70.19M 69.92M 69.75M 69.61M 69.45M 68.9M 69.14M 68.97M 68.66M 68.14M 68.27M
Shares Outstanding (Diluted)
83.4M 82.41M 78.98M 78.03M 77.94M 76.15M 72.32M 71.73M 71M 70.63M 72.66M 70.19M 71.63M 69.75M 71.37M 70.55M 69.29M 69.14M 68.97M 68.66M 68.4M 68.27M
EPS (Basic)
0.33 0.30 0.19 0.25 0.24 0.12 -0.12 -0.18 -0.06 -0.25 0.36 -0.20 0.21 -0.18 0.06 3.23 -0.29 -0.36 -0.53 -0.44 -0.61 -0.72
EPS (Diluted)
0.30 0.27 0.18 0.23 0.23 0.11 -0.12 -0.18 -0.06 -0.25 0.35 -0.20 0.21 -0.18 0.06 3.18 -0.29 -0.36 -0.53 -0.44 -0.61 -0.72
EBITDA
27.67M 33.15M 23.74M 27.54M 23.24M 15.91M -16.58M -6.8M 2.73M -13.81M 2.69M -7.5M -178K -8.23M 7.92M 47.68M -18.17M -22.19M -35.39M -29.59M -39.53M -48.39M
EBIT
27.19M 32.68M 23.27M 27.16M 22.88M 15.57M -16.98M -7.2M 2.3M -14.28M 2.45M -8.5M -1.24M -9.36M 6.84M 46.74M -19.27M -23.29M -36.05M -30.66M -40.55M -49.27M
Depreciation & Amortization
472K 468K 467K 384K 358K 345K 400K 399K 430K 466K 236K 999K 1.06M 1.13M 1.08M 949K 1.1M 1.09M 668K 1.08M 1.02M 883K

© 2026 bestshares.com. All rights reserved.